Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110901 · ClinicalTrials.gov registry record · Phase 3
A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
A Phase 3 study, sponsored by Proteon Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 349
- Enrollment target
NCT02110901 is a Phase 3 study that has completed, run by Proteon Therapeutics. The registered enrollment target is 349 participants.
The verdict
NCT02110901, a Phase 3 study, has completed, sponsored by Proteon Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 349 participants
- Enrollment target
Study Summary
This research study is designed to assess the safety and effectiveness of an experimental drug called PRT-201 in patients both receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. PRT-201 is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.
Interventions
- DRUG Placebo
- DRUG PRT-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02110901
The ClinicalTrials.gov registry entry for NCT02110901 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Proteon Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02110901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02110901 about?
NCT02110901 is a clinical study titled "A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)". This research study is designed to assess the safety and effectiveness of an experimental drug called PRT-201 in patients both receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis....
What is the current status of trial NCT02110901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 349 participants. The study started on 2014-07. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02110901?
The interventions under investigation include: Placebo (DRUG), PRT-201 (DRUG).
Who is sponsoring clinical trial NCT02110901?
This trial is sponsored by Proteon Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.